Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Operating Leases (2019 - 2025)

Allogene Therapeutics' Operating Leases history spans 7 years, with the latest figure at $77.1 million for Q3 2025.

  • For Q3 2025, Operating Leases fell 9.4% year-over-year to $77.1 million; the TTM value through Sep 2025 reached $77.1 million, down 9.4%, while the annual FY2024 figure was $83.2 million, 12.48% down from the prior year.
  • Operating Leases for Q3 2025 was $77.1 million at Allogene Therapeutics, down from $79.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $101.1 million in Q4 2022 and bottomed at $50.6 million in Q3 2021.
  • The 5-year median for Operating Leases is $85.1 million (2024), against an average of $82.2 million.
  • The largest annual shift saw Operating Leases soared 51525.0% in 2021 before it dropped 15.89% in 2025.
  • A 5-year view of Operating Leases shows it stood at $73.1 million in 2021, then skyrocketed by 38.28% to $101.1 million in 2022, then dropped by 5.94% to $95.1 million in 2023, then fell by 12.48% to $83.2 million in 2024, then dropped by 7.34% to $77.1 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Operating Leases are $77.1 million (Q3 2025), $79.2 million (Q2 2025), and $81.3 million (Q1 2025).